Faron

🛜 We’ve launched our new website today! 🛜 The development of the site has focused on clarity and better serving different stakeholders. The website features dedicated sections for investors, patients, as well as information on Faron’s development pipeline and the company itself. We have gathered all reports and presentations on a dedicated page and provide a separate section in accordance with AIM Rule 26 of the London Stock Exchange under the Investors section. Thank you for the feedback received during the day. To visit the new site, see the link in post comments.

Great to hear our CEO Juho Jalkanen MD, PhD on the latest Citeline In Vivo Podcast with Anabel Costa-Ferreira, discussing the importance of addressing unmet medical needs in cancer by breaking treatment resistance – something we’re working towards with the development of bexmarilimab, our wholly owned #immunotherapy candidate.   To listen to the podcast, please visit: https://lnkd.in/eC7K_Ndk   #Faron #podcast #biotech #drugdevelopment #oncology #heatlhcare  

Greetings from the opening day of J.P. Morgan's 43rd Annual Healthcare Conference in San Francisco, USA. It is a privilege to be invited in this premier conference focusing on health care investment and discussing the major themes of healthcare for 2025. 💡 In the pre words for the event, innovation was mentioned as a guiding principle in the biotech sector and oncology as one of the hot therapeutic areas in 2025 by J.P. Morgan analysts.    We look forward to dozens of super-interesting meetings during the coming days! #Faron #biotech #drugdevelopment #oncology #heatlhcare #conference 

Our CEO Juho Jalkanen MD, PhD CMO Petri Bono and CFO Yrjö E K Wichmann will be attending J.P. Morgan’s 43rd Annual Healthcare Conference taking place in San Francisco from 13-16 January.   This premier conference is the largest and most influential healthcare investment symposium of the year, bringing together global industry leaders, fast-growing emerging companies, innovative technology pioneers and key members of the investment community.   Please reach out if you’d like to meet the Faron team and learn more about the progress in clinical development of #bexmarilimab, our wholly owned #immunotherapy candidate.   #Faron #biotech #drugdevelopment #oncology #heatlhcare #conference  

We were thrilled to present the full phase 2 interim data from BEXMAB trial at the 66th American Society of Hematology (ASH) Annual Meeting earlier today! Key takeaways: ✅ 80% overall response rate in r/r MDS patients  ✅ Deep and durable responses: 70% achieved complete response (CR) / marrow complete remission (mCR) / partial response (PR) ✅ 4 patients advanced to receive a bone marrow transplant ✅ Median overall survival estimated at 13.4 months in r/r MDS population Faron will host a virtual webinar to discuss the full analysis of data today, on December 10, 2024, at 16.00 EET/9am ET/6am PT. To register for the event, please visit https://lnkd.in/dQgiAZ8Z The full poster containing the updated clinical data from the BEXMAB trial is available on Faron ‘s website at https://lnkd.in/ddpM9rCT #Faron #bexmarilimab #biotech #drugdevelopment #CancerResearch #Immunotherapy #ASH

Rise and shine from San Diego, ASH 2024! Yesterday was a big day for Faron as we presented our poster in Ash 2024, the world's largest and most comprehensive hematology event of the year. Our title for the poster presentation was Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study. The lead authors (in the picture from left) are Dr. Mika Kontro, MD, PhD, Associate Professor at the University of Helsinki; & Dr. Amer Zeidan, MD, MBBS, MHS, Associate Professor of Medicine, Chief of Hematologic Malignancies Division, Director of Hematology Early Therapeutics Research, and leader of the clinical program and the Clinical Research Team for Leukemia and Myeloid Malignancies at Yale Cancer Center.   We are hosting a virtual webinar to discuss the full analysis of data later today, 10 December 2024 at 16.00 EET/9am ET/6am PT.   To register for the event visit the link in the post comments.   #Faron #bexmarilimab #biotech #drugdevelopment #CancerResearch #Immunotherapy #ASH

Greetings from San Diego, USA! Team Faron Juho Jalkanen MD, PhD, Elina Louramo & Petri Bono is exploring the world's largest and most comprehensive hematology event of the year – the ASH. The event is organized by the American Society of Hematology and held for the 66th time this year – what a remarkable journey for them!    The day was filled with inspiring encounters. Luckily the event can also be attended remotely from every corner of the world, as hematological diseases are a shared concern globally.   We are excited to be here and looking forward to our poster presentation tomorrow – stay tuned!   #Faron #bexmarilimab #biotech #drugdevelopment #CancerResearch #Immunotherapy #ASH

Today we announced that following interaction with UK Regulatory Authorities, our BEXMAB Study, investigating Faron’s wholly-owned #immunotherapy candidate #bexmarilimab in relapsed and refractory myelodysplastic syndrome patients (r/r MDS), has received regulatory approval to be conducted in the UK.    Additionally, bexmarilimab has received an Innovation Passport, under the Innovative Licensing and Access Pathway (ILAP) from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), for the treatment of relapsed/refractory r/r MDS.   The ILAP will provide Faron with enhanced regulatory support from the MHRA and collaborative opportunities with health technology assessment bodies and other stakeholders, highlighting bexmarilimab’s potential to address critical unmet medical needs and positioning the therapy for faster development and potentially earlier access for patients.    Read the full press release here: https://lnkd.in/etcx3r8m     #Faron #biotech #drugdevelopment #oncology

Today, we announced new positive interim phase 2 readout data from our BEXMAB trial. ✨ Key Highlights: ✅ The new data confirmed our earlier positive Phase 1 & 2 findings ✅ 80% Objective Response Rate (ORR) in 20 MDS patients who are refractory or relapsed on HMA (r/r MDS) and have no effective treatment options (up from the ORR of 79% in the data published in May 2024). ✅ Estimated median overall survival (mOS) of 13.4 months, compared to the historical average of 5-6 months typically expected under standard of care. We will present the full data at the 66th ASH Annual Meeting in San Diego, CA, on December 9, 2024. Join us in a virtual webinar to discuss the full analysis of data on Tuesday, December 10, 2024 at 16.00 EET/9am ET. To register, please visit: BEXMAB Study Update To read the full release, please visit: https://lnkd.in/gtPS2m2r #Faron #bexmarilimab #biotech #drugdevelopment #CancerResearch #Immunotherapy #ASH2024 #ActivateYourBodyToDeactiveCancer

We recently announced a patent filing covering the use of soluble Clever-1 for inactivating T-cells to treat autoimmune diseases and inflammatory disorders. This is based on our findings which showed that Clever-1-positive macrophages and endothelial cells secrete a soluble form of Clever-1 which binds to T-cells and inactivates them. Faron and its researchers successfully identified this soluble part of Clever-1. Following this filing, we intend to utilise the soluble Clever-1 or fragments to design the optimal drug for treating autoimmune diseases, with the aim of expanding our pipeline beyond hematological cancers and solid tumor oncology. Read the full press release here: https://lnkd.in/emRYT23E #Faron #biotech #drugdevelopment #Macrophages